NL-OMON21023招募中不适用
T-cell Inhibition by Mycophenolate Mofetil Treatment in Patients Undergoing Carotid Endarterectomy.
Academic Medical CenterAmsterdam, the Netherlands0 个研究点目标入组 50 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 50
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Consecutive patients with carotid artery stenosis (>70% diameter stenosis on angiography or ultrasonography) with ipsilateral transient ischemic attack (TIA) who are planned to undergo carotid endarterectomy (CEA) will be included and treated for a minimum of three weeks prior to surgery. These patients will be recruited at the outpatient department of Vascular Surgery.
排除标准
- •Patients who are unable to tolerate MMF treatment, who withdraw their consent or those with any other medical condition or laboratory abnormality which in the opinion of the principal investigator could affect subject safety, preclude evaluation of response, or render unlikely that the patient would complete the study, are excluded.
研究者
相似试验
已完成
不适用
T-cell Inhibition by Mycophenolate Mofetil Treatment in Patients Undergoing Carotid EndarterectomyVascular diseaseCirculatory SystemISRCTN84092396Academic Medical Center (AMC) (The Netherlands)50
进行中（未招募）
1 期
Influence of mycophenolate mofetil (Cellcept) on the progression of diabetic nephropathyDiabetes mellitus Type 2 with microalbuminuriaEUCTR2008-003768-20-ATMedizinische Universität Wien, Universitätsklinik f. Innere Med. III, Abt. f. Nephrologie u. Dialyse
招募中
不适用
The Effect of Mycophenolate Mofetil and Cyclophosphamide on the Lymphocyte Subsets in Patients With Proliferative Lupus NephritisLupus NephritisNCT02954939The University of Hong Kong50
终止
3 期
Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD)CancerNCT00089141Martin, Paul151
已完成
不适用
Does conversion from Mycophenolate Mofetil (CellCept) to Enteric-coated Mycophenolate Sodium (Myfortic) improve gastrointestinal symptoms in pediatric renal transplant recipients?Kidney transplantInjury, Occupational Diseases, PoisoningISRCTN72965183ovartis Pharmaceuticals Canada Inc.32